766 HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe−) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HepNet.Greece COHORT STUDY

Papatheodoridis, George V.; Manolakopoulos, Spilios; Touloumi, Giota; Nikolopoulou, Georgia; Raptopoulou‐Gigi, M.; Gogos, Charalampos; Zouboulis, I. Vafiadis; Karamanolis, Dimitrios G.; Chouta, A.; Ilias, A.; Drakoulis, C.; Mimidis, Kostas; Ketikoglou, I.; Manesis, E.K.; Mela, Marianna; Hatzis, G.; Dalekos, Georgios N.

doi:10.1016/s0168-8278(13)60768-0

Cited by 7 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In western countries, HBV related HCC is clearly associated with cirrhosis and excessive alcohol intake, 31 whereas in Asia and sub-Saharan Africa, HCC can develop in carriers with mild liver fibrosis due to the long standing infection usually acquired at birth. 32 , 33 Our findings corroborate data from Italy and Greece 31 , 34 as on multivariate analysis, the independent predictors for HCC development despite NUC therapy were older age (aHR: 1.085; 95%CI: 1.021–1.153; p = 0.009) and cirrhosis at baseline (aHR: 4.787; 95%CI: 1.105–20.734; p = 0.036).…”

Section: Discussionsupporting

confidence: 86%

Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score

Magalhães-Costa

Lebre

Peixe

et al. 2016

GE Portuguese Journal of Gastroenterology

View full text Add to dashboard Cite

ObjectiveTo investigate hepatocellular carcinoma (HCC) incidence, risk factors and the performance of baseline REACH-B risk score in a Portuguese chronic hepatitis B (CHB) population on antiviral therapy.MethodsRetrospective study of CHB patients who were treated with tenofovir or entecavir for at least 12 months. Multivariate analysis was performed to identify factors associated with HCC. The Kaplan–Meier method was used to estimate the cumulative incidence of HCC at 1, 3 and 5 years on therapy. The performance of the REACH-B score at baseline was assessed.ResultsOne hundred and twenty patients initiated nucleos(t)ide analogs (NUC) therapy (age, 47 ± 14 years-old; 83 male; 11% had cirrhosis; 71% tenofovir; 73% HBeAg-negative; 61% treatment-naïve). After a median time under NUC of 39 months, 9 patients (7.5%) developed HCC. The calculated cumulative incidence rates of HCC at 1, 3 and 5 years on therapy were 5.1%, 7.3% and 8.8%, respectively. Independent predictors for HCC occurrence: age and cirrhosis at baseline. Diagnostic accuracy of baseline REACH-B score in predicting HCC development: AUC 0.738, 95%CI: 0.521–0.955. The cutoff value of 8 points had a sensitivity, specificity, positive predictive value and negative predictive value of 75%, 52%, 6% and 98%, respectively in predicting HCC occurrence during therapy.ConclusionsOlder age and cirrhosis at baseline were independent predictors for HCC development. Discriminatory performance of baseline REACH-B score was limited.

show abstract

Section: Discussionsupporting

confidence: 86%

Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score

Magalhães-Costa

Lebre

Peixe

et al. 2016

GE Portuguese Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Probabilities representing the likelihood of HBV‐related events were identified from literature reviews and expert sources (5–29) (Table 1).…”

Section: Methodsmentioning

confidence: 99%

Cost effectiveness of screening immigrants for hepatitis B

Wong

Heathcote

Krahn

2011

Liver International

View full text Add to dashboard Cite

show abstract

“…27,28 Even with low viral load, fibrotic burden was an important predictor of HCC development in patients with CHB. 12,29 Similarly, the CU-HCC score of patients with cirrhosis and without HCC development was higher than that of patients without cirrhosis and with HCC development. This means that liver fibrosis is important for HCC development and AVT could suppress HCC development through improvement of fibrosis.…”

Section: Discussionmentioning

confidence: 96%

Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B

Chon

Lee

et al. 2021

Hepatology Research

View full text Add to dashboard Cite

Aim Risk prediction models for hepatocellular carcinoma (HCC) development are available. However, the influence of antiviral therapy (AVT) on these models in patients with chronic hepatitis B is unknown. Methods The dynamic changes in risk prediction models during AVT and the association between risk prediction model and the risk of chronic hepatitis B‐related HCC development were investigated. Between 2005 and 2017, 4917 patients with chronic hepatitis B (3361 noncirrhotic, 1556 cirrhotic) were recruited. Results The mean age of the study population was 49.3 years and 60.6% (n = 2980) of the patients were male. The mean Chinese University‐HCC (CU‐HCC) score was 12.7 at baseline in the overall study population, and decreased significantly (mean, 8.7) after 1 year of AVT (p < 0.001). The score was maintained throughout 5 years of AVT (mean, 8.4–8.8; p > 0.05). The proportion of high‐risk patients (CU‐HCC score ≥ 20) was 28.9% at baseline, and decreased significantly after 1 year of AVT (5.0%; p < 0.001), and remained stable through 5 years of AVT (2.2%–3.6%; p > 0.05). In addition to the score at baseline, the CU‐HCC score at 1 year of AVT independently predicted the risk of HCC development (hazard ratio = 1.072; p < 0.001), together with male gender and platelet count (all p < 0.05). Conclusions The CU‐HCC score significantly decreased at 1 year of AVT and was maintained thereafter. The CU‐HCC score after 1 year of AVT independently predicted the risk of HCC development in patients with chronic hepatitis B.

show abstract

766 HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe−) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HepNet.Greece COHORT STUDY

Cited by 7 publications

References 0 publications

Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score

Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score

Cost effectiveness of screening immigrants for hepatitis B

Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B

Contact Info

Product

Resources

About